Pathkey.ai Limited has released a press release.
Changes to Board of Directors
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Pathkey.AI
- Pause in Trade
- Appendix 4C - monthly
- Cancer Trials Australia becomes MediaConsent collaborator
- Capital Raise and Strategic Acquisition of Ludomade
- Collaboration announced with Neuroscience Trials Australia
Later from Pathkey.AI
- Reinstatement to Trading on the ASX
- Half Year Financial Report & Appendix 4D
- Michelle Gallaher appointed SRO CEO
- Response to Appendix 4C Query
- Non-Renounceable Entitlement Offer and Company Update
Follow Pathkey.AI into a list and get an email when it puts out news.
Follow Pathkey.AI